Heron Patrick J 4

What Happened

• Patrick J. Heron, a director of Mirum Pharmaceuticals (MIRM), received two awards on June 15, 2026: 3,772 derivative shares (awarded as option-type shares) and 1,980 deferred stock units. Both awards were granted at $0.00 per share (no cash paid at grant).
• Total awarded = 5,752 shares (derivative instruments). These are grants/awards (transaction code A), not open-market purchases or sales, so they represent compensation/long-term incentives rather than immediate buying or selling activity.

Key Details

• Transaction date: 2026-06-15; filing date: 2026-06-17 (filed within the normal 2-business-day Form 4 window).
• Price: $0.00 per share for both awards.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: The 3,772 award vests on the first anniversary of the grant date and will be fully vested by the Issuer's 2027 annual stockholder meeting.
  • F2: Each of the 1,980 deferred stock units represents a contingent right to one share, vests on the first anniversary (or by the 2027 annual meeting) and will be paid in common stock upon a change in control or within 60 days after separation from service.
• No 10b5-1 plan, tax-withholding sale, or immediate sale of shares was reported.

Context

• These grants are typical director compensation intended to align management and director interests with shareholders. Because they are derivative awards and subject to vesting, they do not represent immediate economic gain or an outright purchase of stock.
• The deferred stock units have payout triggers (change in control or separation) and a time-based vesting schedule; until vested or converted to common stock they remain contingent rights.